Glenmark gets approval for favipiravir as Covid-19 treatment in India

Glenmark gets approval for favipiravir as Covid-19 treatment in India

Glenmark Pharmaceuticals Ltd had received an approval from India’s drugs regulator to make and sell oral antiviral drug favipiravir for treating mild-to-moderate Covid-19 patients in the country

Glenmark gets approval for favipiravir: It is the first company in the country to receive such approval from the Controller General of India (DCGI). The company said in a statement that it has prepared the raw material (API) internally for this drug. He has also developed its compound (formulation).

Favipiravir is an anti-viral drug. This drug has shown the correct response against influenza virus. The use of this medicine for the treatment of influenza virus is permitted in Japan.

Read this too: https://capitalboat.in/airtel-buys-10-stake-in-education-sector-startup-company-lattu-media/

Leave a Reply

Your email address will not be published. Required fields are marked *